Eric M. Horwitz, MD, FABS, FASTRO

E Horwitz 2024
(4.9/5.0)
119 Patient Satisfaction Ratings

Request an Appointment

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427
  • Fox Chase Cancer Center - Voorhees
    502 Centennial Blvd
    Suite 7
    Voorhees, NJ 08043
    Phone: 888-369-2427

Chair, Department of Radiation Oncology, Lewis Katz School of Medicine at Temple University

Chair, Department of Radiation Oncology, Fox Chase Cancer Center

Professor

Gerald E. Hanks Endowed Chair in Radiation Oncology

NCCN, Prostate Cancer Panel Member

Specialties

  • Genitourinary Radiation Oncology
  • Radiation Oncology

Areas of Expertise

Urethral Cancer, Penile Cancer, Ureteral Cancer, Kidney Cancer, Testicular Cancer, Bladder Cancer, Prostate Cancer

Treatment Focus

  • Intensity Modulated Radiation Therapy (IMRT)
  • Stereotactic body Radiation Therapy (SBRT)
  • HDR temporary prostate brachytherapy
  • LDR permanent prostate brachytherapy

Distinctions

Treatment Philosophy

In addition to my focus on treating and caring for patients with prostate and bladder cancer, it is my responsibility as Chairman of the Department of Radiation Oncology at Fox Chase; an NCI designated National Comprehensive Cancer Center to promote the mission of the Center to prevail over cancer. Our department's expertise has always focused on developing and integrating sophisticated technology into successful treatment for our cancer patients and I remain committed to continuing and expanding this legacy. However, the successful treatment of a patient is not just based on the technology that is available. Being diagnosed with cancer and receiving treatment is one of the most difficult things that many people will ever face, and it is crucial that we as caregivers do not forget this. Caring for patients as one important part of a multidisciplinary team allows us in the Department of Radiation Oncology to provide the best possible care for our patients.

 

Chair, Radiation Oncology

The mission of Fox Chase Cancer Center Radiation Oncology is to alleviate the burden of cancer by safely and compassionately delivering state-of-the-art radiation therapy with a commitment to clinical excellence, research expertise, and education in an inclusive environment that embraces diversity.


The Department of Radiation Oncology at Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University offer many of the most sophisticated radiation techniques, including adaptive radiation therapy, hypofractionated intensity modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SbRT), high-dose-rate (HDR) brachytherapy, and the GammaKnife radiosurgery system. We have some of the most extensive experience in adaptive radiation therapy and HDR brachytherapy in the region and country.


But we believe caring for people with cancer is more than just a collection of technologies.  Although crucial to delivering state-of-the-art treatment, advanced technologies are just one component of what we have to offer our patients. As part of a National Cancer Institute-designated Comprehensive Cancer Center, we believe that cancer care is truly multidisciplinary, so we work with our Fox Chase colleagues, many of whom are national and international experts in surgical and medical oncology. This level of expertise and care offers our patients the best opportunity for treatment success.


The Fox Chase Department of Radiation Oncology is one department located at four sites in Northeast Philadelphia, Bucks County, Montgomery County, and North Philadelphia. This gives cancer patients in Southeastern Pennsylvania, New Jersey, and Delaware access to Fox Chase Radiation Oncology regardless of location.


In addition to providing state-of-the-art care, Fox Chase radiation oncologists are involved in developing new treatments through research. The foundation of modern cancer care rests on clinical, basic science, and translational research. We have a decades-long history of developing many of the treatments that are now standard, including 3D conformal radiation therapy, IMRT, and image-guided radiation therapy. We are a department of firsts, including the first CT simulator (1989) and the first MRI simulator (2000) in the United States. The first temporary HDR prostate implant on the East Coast was performed at Fox Chase in 1998, and now we are the first and only department in the United States developing and treating patients with radiodynamic therapy.


Fox Chase Radiation Oncology is also looking to the future, as evidenced by its commitment to train the next generation of radiation oncologists, medical physicists, and radiation therapists. We have been training radiation oncologists in our residency program for more than 40 years and we remain a top choice for elite medical students from around the country. Education is a priority for the radiation oncology and medical physics faculty, and preparing the next generation of clinicians and physicists is one of our key missions.
 

Through clinical excellence, research innovation, and educational distinction, Fox Chase Radiation Oncology offers the highest level of care for our patients in their time of need.
 

 

Educational Background

  • Resident, Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
  • MD, Albany Medical College, Albany, NY, 1992
  • BA, History, Chemistry minor, University of Pennsylvania, Philadelphia, PA, 1988

Certifications

  • American Board of Radiology - Radiation Oncology

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • Prostate Cancer Panel
  • American Society of Radiation Oncology (ASTRO)
  • American Brachytherapy Society (ABS)
  • American Board of Radiology (ABR)
  • American Medical Association (AMA)

Honors & Awards

  • Fellow, American Society of Radiation Oncology (ASTRO), 2017
  • Inaugural Fellow, American Brachytherapy Society (ABS), 2017
  • Volunteer Service Award, American Board of Radiology, 2014, 2022-2025
  • Philadelphia Magazine Top Doctors, 2002-2025
  • Best Doctors in America® , 2013-14, 2019-2025, Radiation Oncology
  • America’s Top Doctors®, 2015-25
  • Newsweek Top Cancer Doctors, 2015
  • Distinguished Service Award, American Brachytherapy Society, 2010
     
Link to /sites/default/files/styles/patient_story/public/images/patient-stories/111078.jpeg?h=36ee178d&itok=zl0rLtmI

Walter Masinick

  • Prostate Cancer

The biopsy came back positive even though all my prostate-specific antigen (PSA) tests were normal at the time. The doctor suggested I get checked in about a year, but I wanted something done sooner and decided to get a second opinion.

VIEW PATIENT STORY

Research Interests

  • Determining outcomes in treatment for prostate cancer patients treated with external beam radiation and brachytherapy
  • Developing image guidance techniques for prostate cancer radiation
  • Developing new bladder preservation techniques to treat patients with muscle invasive bladder cancer

Selected Publications

Shulman R.M., Weinberg D.S., Ross E.A., Ruth K., Rall G.F., Olszanski A.J., Helstrom J., Hall M.J., Judd J., Chen D.Y.T., Uzzo R.G., Dougherty T.P., Williams R., Geynisman D.M., Fang C.Y., Fisher R.I., Strother M., Huelsmann E., Adige S., Whooley P.D., Zarrabi K., Gupta B., Iyer P., McShane M., Yankey H., Lee C.T., Burbure N., Laderman L.E., Giurintano J., Reiss S.,Horwitz E.M., Adverse events reported by patients with cancer after administration of a 2-dose mrna covid-19 vaccine. J Natl Compr Canc Netw. 20(2): 160-166, 2022. https://www.ncbi.nlm.nih.gov/pubmed/35130494.

Vapiwala N., Wong J.K., Handorf E., Paly J., Grewal A., Tendulkar R., Godfrey D., Carpenter D., Mendenhall N.P., Henderson R.H., Stish B.J., Vargas C., Salama J.K., Davis B.J.,Horwitz E.M., A pooled toxicity analysis of moderately hypofractionated proton beam therapy and intensity modulated radiation therapy in early-stage prostate cancer patients. Int J Radiat Oncol Biol Phys. 110(4): 1082-1089, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33539968.

Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology:Jco1802158, 2019. PubMed

Martin, J.M., Li, T., Johnson, M.E., Murphy, C.T., Howald, A.G., Smaldone, M.C., Kutikov, A., Chen, D.Y., Viterbo, R., Greenberg, R.E., Uzzo, R.G., Horwitz, E.M. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center.  J Natl Compr Canc Netw  13:  525-30; 2015. PubMed

Horwitz, E.M. and Weinberg, D.S.  Medicare physician payment data: Is this transparency?  Ann. Int. Med.  161(4):  291-292; 2014. PubMed

Horwitz EM. ABS brachytherapy consensus guidelines. Brachytherapy. 11(1):  4-5, 2012. PubMed

Davis BJ, Horwitz EM, Lee WR, Crook, J. M.; Stock, R. G.; Merrick, G. S.; Butler, W. M.; Grimm, P. D.; Stone, N. N.; Potters, L.; Zietman, A. L.; Zelefsky, M. J.  American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.  Brachytherapy 11(1):6-19, 2012. PubMed

Crook, J.M.; O'Callaghan, C.J.; Duncan, G.; Dearnaley, D.P.; Higano, C.S.; Horwitz, E.M.; Frymire, E.; Malone, S.; Chin, J.; Nabid, A.; Warde, P.; Corbett, T.; Angyalfi, S.; Goldenberg, S.L.; Gospodarowicz, M.K.; Saad, F.; Logue, J.P.; Hall, E.; Schellhammer, P.F.; Ding, K.; Klotz, L.  Intermittent androgen suppression for rising PSA level after radiotherapy.  New England Journal of Medicine 367:  895-903; 2012. PubMed

Rosenthal, S.A.; Bittner, N.H.; Beyer, D.C.; Demanes, D.J.; Goldsmith, B.J.; Horwitz, E.M.; Ibbott, G.S.; Lee, W.R.; Nag, S.; Suh, W.W.; Potters, L.  American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.  International Journal of Radiation Oncology Biology Physics 79:  335-41; 2011.  PubMed

Horwitz, E.M.  Why External Beam Radiotherapy Is Treatment of Choice for Most Men With Early-stage Nonmetastatic Prostate Cancer.  Urology 73:  470-472; 2009. PubMed

... Expand

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Overall Care
4.9
Explained Things Clearly
4.9
Showed Courtesy & Respect
5.0
Discussed Treatment Options
4.9
Recommend Provider
5.0

Patient comments

4.9 out of 5 (119 ratings, 19 comments)
06/03/2025

It was a telehealth visit. The conversation with the doctor was preceded by a conversation with his nurse and a resident


05/20/2025

Televisit helped tremendously.


05/20/2025

Very very professional


05/19/2025

Very impressed with the knowledge and caring exhibited by the doctor and associates.


05/12/2025

I am now considering scheduling of the provider's recommended treatment.!!